
样式: 排序: IF: - GO 导出 标记为已读
-
Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED-AHF): A prospective, randomized, mechanistic study Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-02
Jan Biegus, Gracjan Iwanek, Jeffrey Testani, Robert Zymliński, Marat Fudim, Mateusz Guzik, Piotr Gajewski, Piotr Ponikowski -
Profiling hypotension in heart failure based on office, orthostatic and ambulatory blood pressure measurements Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-02
Anzhela Soloveva, Darya Fedorova, Sabina Kuchinskaia, Amina Rakisheva, Victoria Galenko, Andrey Kozlenok, Svetlana VillevaldeClick on the article title to read more.
-
Lung ultrasound and mortality in a cardiogenic shock population: A prospective registry-based analysis Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-30
Guido Tavazzi, Costanza Natalia Julia Colombo, Matteo Pagnesi, Maurizio Bertaina, Andrea Montisci, Simone Frea, Marco Marini, Martina Briani, Lisa Patrini, Francesca Rossi, Letizia Bertoldi, Giulia Maj, Giovanna Viola, Carlotta Sorini Dini, Serafina Valente, Gaetano Maria De Ferrari, Nuccia Morici, Federico Pappalardo, Alice Sacco -
Insights into the European heart failure epidemiology Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-30
Petar M. Seferović, Marija Polovina, Gianluigi Savarese, Ivan Milinković, Dejana Stanisavljević, Lars Lund, Ovidiu Chioncel, Magdy Abdelhamid, Yuri Lopatin, Stefan Störk, Manuel Anguita Sanchez, Massimo Piepoli, Aldo P. Maggioni, Ewa Jankowska, Antoni Bayes‐Genis, Alain Cohen Solal, Arsen Ristić, Mariya Tokmakova, Mehmet Birhan Yilmaz, Hadi Skouri, Davor Miličić, Offer Amir, Amina Rakisheva, GerasimosAimsThe Heart Failure Association (HFA) of the European Society of Cardiology (ESC), together with the National Heart Failure Societies (NHFS), designed the European Heart Failure (HF) Survey with an aim of assessing contemporary HF epidemiology, management resources, availability and reimbursement of guideline‐directed medications and devices, and structure of professional and patient organizations
-
Global heart failure epidemiology versus enrolment in pivotal trials: A formidable mismatch Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-29
Guillaume Baudry, Guowei Li, Ruoting Wang, Rebecca A.V. Newton, Luca Monzo, Nicolas Girerd, Ana Mocumbi, Faiez Zannad, Harriette G. C. Van SpallAimsRandomized clinical trials (RCTs) that inform international clinical practice guidelines should adequately represent regions burdened with disease. We aimed to assess the geographic representativeness of pivotal heart failure (HF) RCTs using two methodological approaches.Methods and resultsWe assessed the global geographic distribution of HF cases using the Global Burden of Disease 2021 dataset
-
Kidney injury in patients with heart failure‐related cardiogenic shock: Results from an international, multicentre cohort study Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-29
Jonas Sundermeyer, Caroline Kellner, Benedikt N. Beer, Lisa Besch, Angela Dettling, Letizia Fausta Bertoldi, Stefan Blankenberg, Jeroen Dauw, Dennis Eckner, Ingo Eitel, Tobias Graf, Patrick Horn, Joanna Jozwiak‐Nozdrzykowska, Paulus Kirchhof, Stefan Kluge, Axel Linke, Ulf Landmesser, Enzo Lüsebrink, Nicolas Majunke, Norman Mangner, Sven Möbius Winkler, Peter Nordbeck, Martin Orban, Federico Pappalardo -
Albuminuria as a diagnostic criterion and a therapeutic target in heart failure and other cardiovascular disease Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-28
Biykem Bozkurt, Patrick Rossignol, Joseph A. Vassalotti -
Clinical and financial implications of inpatient and outpatient management of worsening heart failure Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-27
Stephen J. Greene, Lisa A. Kaltenbach, Gregg C. Fonarow, Karen Chiswell, Veraprapas Kittipibul, Hubert B. Haywood, Muhammad Shahzeb Khan, Bradley G. Hammill, Javed Butler, Adrian F. Hernandez, G. Michael Felker -
What's new in heart failure? May 2025 Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-26
Mert Tokcan, Julian Hoevelmann, Philipp Markwirth, Bernhard HaringClick on the article title to read more.
-
Issue Information Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-26
Click on the article title to read more.
-
Longitudinal blood pressure and cardiovascular outcomes in heart failure: An individual patient data pooling analysis of clinical trials Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-24
Jing‐Wei Li, Jiang Wang, Yunlong Chen, Hao Yang, Yi Wang, Xia Wang, Jingjng Xiao, Ying Wang, Dehui Qian, Shiyong Yu, Xiaohui Zhao, Hu Tan, Jun Jin, Xin Du, Craig S. AndersonAimsPrevious analyses of the relationship between blood pressure (BP) and heart failure (HF) outcomes have primarily used baseline values rather than longitudinal measurements. We aimed to elucidate associations between longitudinal BP and clinical outcomes in patients with HF with reduced ejection fraction (HFrEF), mildly reduced ejection fraction (HFmrEF), and preserved ejection fraction (HFpEF)
-
Genotype‐guided cardiac device intervention in LMNA‐related cardiac conduction disorder: The need for timely genetic testing Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-24
Shunsuke Inoue, Zhehao Dai, Tsukasa Oshima, Seitaro Nomura, Takashi Hiruma, Ryo Abe, Kanna Fujita, Manami Katoh, Toshiyuki Ko, Yu Shimizu, Masamichi Ito, Kenichiro Yamagata, Junichi Ishida, Eisuke Amiya, Masaru Hatano, Norifumi Takeda, Hiroyuki Morita, Katsuhito Fujiu, Norihiko Takeda, Issei KomuroSudden cardiac death is a catastrophic event, making its prevention important. However, patient selection for primary prevention remains controversial. We report two cases of cardiac conduction disorder initially treated with permanent pacemaker implantation. Genetic testing later revealed novel pathogenic variants in LMNA, leading to an upgrade to implantable cardioverter‐defibrillator for primary
-
Renal denervation improves cardiac function and exercise duration in a miniswine model of heart failure with preserved ejection fraction Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-22
David J. Lefer, Thomas E. Sharp, Amy L. Scarborough, Amelia G. Haydel, Sanjiv J. Shah, Zhen Li, Traci T. GoodchildAimsOveractivity of the sympathetic nervous system is a common underlying mechanism in development and progression of several heart failure with preserved ejection fraction (HFpEF) comorbidities. Decreasing renal sympathetic nerve activity using catheter‐based renal denervation (RDN) systems have shown efficacy in treating resistant hypertension and cardiac dysfunction in heart failure with reduced
-
Recurrent event analyses in patients receiving maintenance dialysis and the effect of higher‐ versus lower‐dose chronic intravenous iron therapy: A report focusing on heart failure events from the PIVOTAL trial Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-21
Stefan D. Anker, Michele Robertson, John J.V. McMurray, Pardeep S. Jhund, Claire White, Chante Reid, Sunil Bhandari, Ken Farrington, Philip A. Kalra, Khawaja M. Talha, Patrick B. Mark, Charles R.V. Tomson, David C. Wheeler, Chris G. Winearls, Iain C. Macdougall, Ian FordAimsIn the PIVOTAL trial, a proactive high‐dose regimen of intravenous iron sucrose, compared to a lower‐dose reactive regimen, reduced the risk of first and recurrent events of the primary endpoint in haemodialysis patients. We present the various approaches of recurrent event analyses for the primary endpoint and for the composite of cardiovascular (CV) death or heart failure hospitalization and
-
DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure (DIGIT-HF): Baseline characteristics compared to recent randomized controlled heart failure trials Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-19
Udo Bavendiek, Nele Henrike Thomas, Dominik Berliner, Xiaofei Liu, Johannes Schwab, Andreas Rieth, Lars S. Maier, Sven Schallhorn, Eleonora Angelini, Samira Soltani, Fabian Rathje, Mircea-Andrei Sandu, Welf Geller, Thomas Gaspar, Rainer Hambrecht, Marija Zdravkovic, Sebastian Philipp, Dragana Kosevic, Georg Nickenig, Daniel Scheiber, Sebastian Winkler, Peter Moritz Becher, Philipp Lurz, Martin Hülsmann -
Incident heart failure is common and underrecognized in patients with biopsy‐proven metabolic dysfunction‐associated steatotic liver disease Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-20
Kara Wegermann, Fouad Chouairi, Georgia Sofia Karachaliou, Carolyn Ahlers, Sandra Au, Kaela Miller, Tor Biering‐Sørensen, Manal F. Abdelmalek, Anna Mae Diehl, Cynthia A. Moylan, Marat Fudim -
A simplified approach for diagnosing heart failure with preserved ejection fraction by assessing the left atrium and natriuretic peptides Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-20
Jerremy Weerts, Arantxa Barandiarán Aizpurua, Ravi B. Patel, Arno A. van de Bovenkamp, Hesam Amin, Sandra Sanders‐van Wijk, Sanne G.J. Mourmans, Anouk Achten, M. Louis Handoko, Antoni Bayés‐Genís, Hans‐Peter Brunner‐La Rocca, Sanjiv J. Shah, Christian Knackstedt, Vanessa P.M. van Empel -
Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: The VELOCITY study Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-20
Stephen J. Greene, Stefano Corda, Ciaran J. McMullan, Giovanni Palombo, Christina Schooss, Vanja Vlajnic, Katrin Walkamp, Michele SenniAimsIn clinical practice, simplifying the number of medication titration steps while maintaining safety may improve the likelihood of patients with heart failure (HF) achieving target doses of guideline‐directed medical therapy (GDMT). The VELOCITY study examined whether removing the 2.5 mg initiation step for vericiguat, and instead initiating therapy at 5 mg daily, would be safe and well‐tolerated
-
Home‐based urinary sodium monitoring via point‐of‐care testing for personalized diuretic titration in heart failure management: The EASY‐STOP study Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-20
Evelyne Meekers, Pieter Martens, Ruben Knevels, Marie Miseur, Athanasius Ezzat, François Croset, Jeroen Dauw, Henri Gruwez, Sebastiaan Dhont, Jonas Erzeel, Marnicq Van Es, Petra Nijst, Frederik H. Verbrugge, Matthias Dupont, Stefan Janssens, Wilfried Mullens -
Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-16
Misato Chimura, Mingming Yang, Alasdair D. Henderson, Pardeep S. Jhund, Kieran F. Docherty, Brian L. Claggett, Akshay S. Desai, Gerasimos Filippatos, Grzegorz Gajos, Katharina Mueller, Andrea Glasauer, Katja Rohwedder, Prabhakar Viswanathan, Carolyn S.P. Lam, Naoki Sato, Michele Senni, Adriaan A. Voors, Faiez Zannad, Mehmet B. Yilmaz, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V.Anaemia is common in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and associated with poor clinical outcomes. While renin–angiotensin system blockers reduce haemoglobin, little is known about the effect of mineralocorticoid receptor antagonists on haemoglobin and in patients with anaemia. We evaluated the effects of finerenone according to anaemia status in patients
-
Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-16
Jonathan W. Cunningham, Brian L. Claggett, Muthiah Vaduganathan, Akshay S. Desai, Pardeep S. Jhund, Carolyn S.P. Lam, Michele Senni, Sanjiv Shah, Adriaan Voors, Faiez Zannad, Bertram Pitt, Flaviana Amarante, James Lay‐Flurrie, Katja Rohwedder, Laura Goea, Mario Berger, John J.V. McMurray, Scott D. SolomonAimsN‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) concentrations serve as markers of prognosis and therapeutic response in patients with heart failure (HF). The effect of the non‐steroidal mineralocorticoid receptor antagonist finerenone on NT‐proBNP in patients with HF with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) is currently unknown.Methods and resultsThe FINEARTS‐HF
-
Effect of pulmonary artery pressure‐guided management on outcomes of patients with heart failure outside clinical trials: A systematic review and meta‐analysis of real‐world evidence with the CardioMEMS Heart Failure System Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-14
Chris J. Kapelios, Sotiria Liori, Michael Bonios, William T. Abraham, Gerasimos Filippatos -
Characterization of arrhythmia‐induced cardiomyopathy using magnetic resonance imaging in patients with persistent atrial fibrillation and left ventricular systolic dysfunction – insights from DECAAF II Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-13
Ala Assaf, Han Feng, Mayana Bsoul, Ghassan Bidaoui, Hadi Younes, Christian Massad, Mario Mekhael, Charbel Noujaim, Omar Kreidieh, Swati Rao, Amitabh Pandey, Philipp Sommer, Christian Mahnkopf, Nassir Marrouche, Christian Sohns -
Further considers on the FINEARTS‐HF trial Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-12
Chang Liu, Min CaoClick on the article title to read more.
-
Reply to ‘Further considerations on the FINEARTS‐HF trial’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-12
Jawad H. Butt, John J.V. McMurrayWe thank the authors for acknowledging our work. The diagnosis of previously unknown diabetes and pre-diabetes was based on only one measurement of glycated haemoglobin and not at least two measurements or supplementary analyses of non-fasting glucose, fasting glucose, and oral glucose tolerance, as recommended. Therefore, it is possible that some patients might have been recategorized. However, we
-
Reply to the letter regarding the article ‘Lower extremity lymphatic flow is associated with diuretic response in acute heart failure’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-12
Barbara Ponikowska, Jan BiegusClick on the article title to read more.
-
Letter regarding the article ‘Lower extremity lymphatic flow is associated with diuretic response in acute heart failure’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-12
Chao Yang, Beibei Gao, Jinyu HuangClick on the article title to read more.
-
Reply to ‘Assessing heart failure after surgical occlusion of the left atrial appendage’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-08
Philipp Krisai, Richard P. Whitlock, Jeff S. HealeyClick on the article title to read more.
-
Assessing heart failure after surgical occlusion of the left atrial appendage. Letter regarding the article ‘Heart failure after left atrial appendage occlusion: Insights from the LAAOS III randomized trial’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-08
Claudia Stöllberger, Josef Finsterer, Birke SchneiderClick on the article title to read more.
-
Aetiological phenotypes of atrial and ventricular secondary tricuspid regurgitation and their prognostic implications: insights from the CARE‐TR registry Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-08
Laura Lupi, Elena Antonioli, Angelica Praderio, Alessandro Villaschi, Elisa Soranzo, Nicola Saccani, Kamil Stankowski, Daniele Cocianni, Beniamino Pagliaro, Valeria Magni, Marco Loffi, Daniela Tomasoni, Matteo Pagnesi, Antonio Mangieri, Davide Stolfo, Gianfranco Sinagra, Marianna Adamo, Marco Metra -
Donor heart allocation systems in Europe. A scientific statement of the Heart Failure Association of the ESC Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-08
Hoong Sern Lim, Kevin Damman, Guillaume Baudry, Maja Cikes, Stamatis Adamopoulos, Tuvia Ben‐Gal, Nicolas Girerd, Andreas Zuckermann, Marco Masetti, Sanem Nalbantgil, Laurens Tops, Piotr Ponikowski, Maria Crespo‐Leiro, Frank Ruschitzka, Marco Metra, Finn GustafssonHeart transplantation remains the gold standard for treatment of most patients with advanced heart failure (HF), but despite improvements of organ recovery and utilization, donor heart scarcity remains a critically limiting factor. Detailed heart allocation systems (HASs) are in place to ensure use of organs for appropriate candidates, In Europe multiple, different HASs have evolved in different countries
-
Heart failure and obesity: Translational approaches and therapeutic perspectives. A scientific statement of the Heart Failure Association of the ESC Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-07
Gianluigi Savarese, Gabriele G. Schiattarella, Felix Lindberg, Markus S. Anker, Antoni Bayes‐Genis, Magnus Bäck, Frieder Braunschweig, Chiara Bucciarelli‐Ducci, Javed Butler, Antonio Cannata, Federico Capone, Ovidiu Chioncel, Emilia D'Elia, Arantxa González, Gerasimos Filippatos, Nicolas Girerd, Jean‐Sébastien Hulot, Carolyn S.P. Lam, Lars H. Lund, Christoph Maack, Brenda Moura, Mark C. Petrie, MassimoObesity and heart failure (HF) represent two growing pandemics. In the general population, obesity affects one in eight adults and is linked with an increased risk for HF. Obesity is even more common in patients with HF, where it complicates the diagnosis of HF and is linked with worse symptoms and impaired exercise capacity. Over the past few years, new evidence on the mechanisms linking obesity with
-
Residual tricuspid regurgitation after tricuspid valve interventions: What do we know? Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-06
Lukas Stolz, Charles Davidson, Volker Rudolph, Jörg HausleiterIntroduction Tricuspid regurgitation (TR) is a major health burden being associated with substantial morbidity, mortality and quality of life (QoL) impairment.1 Advancements in transcatheter tricuspid valve interventions (TTVI) have significantly changed the landscape of tricuspid valve (TV) disease enabling treatment of elderly patients at advanced or prohibitive surgical risk. TV transcatheter edge-to-edge
-
Pathophysiology and clinical use of agents with vasodilator properties in acute heart failure. A scientific statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-05
Ovidiu Chioncel, Alexandre Mebazaa, Dimitrios Farmakis, Magdy Abdelhamid, Lars H. Lund, Veli‐Pekka Harjola, Stefan Anker, Gerasimos Filippatos, Tuvia Ben‐Gal, Kevin Damman, Hadi Skouri, Laura Antohi, Sean P. Collins, Marianna Adamo, Oscar Miro, Loreena Hill, John Parissis, Brenda Moura, Christian Mueller, Ewa Jankowska, Yury Lopatin, Mark Dunlap, Maurizio Volterrani, Marat Fudim, Andreas J. Flammer -
Mitochondrial targets in ischaemic heart disease and heart failure, and their potential for a more efficient clinical translation. A scientific statement of the ESC Working Group on Cellular Biology of the Heart and the ESC Working Group on Myocardial Function Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-05
Melanie Paillard, Mahmoud Abdellatif, Ioanna Andreadou, Christian Bär, Luc Bertrand, Bianca J.J.M. Brundel, Gemma Chiva‐Blanch, Sean M. Davidson, Dana Dawson, Fabio Di Lisa, Paul Evans, Zoltan Giricz, Derek J. Hausenloy, Petra Kleinbongard, Frank Lezoualc'h, Elisa Liehn, Christoph Maack, Ange Maguy, Elizabeth Murphy, Cinzia Perrino, Maurizio Pesce, Peter P. Rainer, Katrin Streckfuss‐Bömeke, Matthias -
Video thermography uncovers relationship between volume status and temperature in heart failure Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-05
Pawel Rubiś, Adam Piórkowski, Mateusz Winiarczyk, Karolina Nurzyńska, Ewa Dziewięcka, Sylwia Wiśniowska‐Śmiałek, Mariusz Marzec, Julia Lasek, John G.F. Cleland, Piotr AugustyniakAimsThermoregulation is a fundamental aspect of mammalian homeostasis. Skin blood flow has a key role to play in thermoregulation. Heart failure (HF) can disrupt thermoregulation. Infrared thermography (IRT) offers a non‐invasive method to map skin temperature (Ts). The aim of this study was to investigate the relationships between IRT‐assessed thermoregulation, circulatory volume, and exercise in
-
Association between liver fibrosis, plasma volume status, and cardiovascular mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-04
Nobuo Sasaki, Yoshitaka Ueno, Ryoji Ozono, Yukiko Nakano, Yukihito Higashi -
Cancer therapy‐related cardiotoxicity is associated with distinct alterations of the myocardial lipidome Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-02
Vera M. Braun, Anna Foryst‐Ludwig, Ulf Landmesser, István Baczkó, Hendrik Milting, Ulrich Kintscher, Niklas Beyhoff -
Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR‐HF2‐DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trials Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-30
Stefan D. Anker, Tim Friede, Javed Butler, Khawaja M. Talha, Marius Placzek, Monika Diek, Anna Nosko, Adriane Stas, Stefan Kluge, Dominik Jarczak, Geraldine Deheer, Meike Rybczynski, Antoni Bayes‐Genis, Frank Edelmann, Gerasimos Filippatos, Gerd Hasenfuß, Wilhelm Haverkamp, Mitja Lainscak, Ulf Landmesser, Iain C. Macdougall, Bela Merkely, Burkert M. Pieske, Fausto J. Pinto, Tienush Rassaf, Maurizio -
The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS‐HF Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-30
Toru Kondo, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Meike Brinker, James Lay‐Flurrie, Patrick Schloemer, Prabhakar Viswanathan, Flaviana Amarante, Chern‐En Chiang, Gerasimos Filippatos, Carolyn S.P. Lam, Mark C. Petrie, Michele Senni, Morten Schou, Subodh Verma, Adriaan A. Voors, Dirk von Lewinski, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon -
Integrated role of cardiac magnetic resonance and genetics in predicting left ventricular reverse remodelling in dilated and non‐dilated cardiomyopathy Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-29
Martina Setti, Manuela Iseppi, Job A.J. Verdonschot, Jacopo G. Rizzi, Alessia Paldino, Carola Pio Loco Detto Gava, Giulia Barbati, Matteo Dal Ferro, Max F.G.H.M. Venner, Anne G. Raafs, Marta Gigli, Davide Stolfo, Antonio De Luca, Giulia De Angelis, Teresa M. Capovilla, Sharon Graw, Flavio L. Ribichini, Matthew Taylor, Luisa Mestroni, Stephane R.B. Heymans, Gianfranco Sinagra, Marco Merlo -
Issue Information Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-27
Click on the article title to read more.
-
What's new in heart failure? April 2025 Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-27
Alberto Aimo, Pau Codina, Matthew M.Y. Lee, Daniela Tomasoni, Michael BöhmClick on the article title to read more.
-
Remote pulmonary artery pressure‐guided management of patients with heart failure: A clinical consensus statement of the Heart Failure Association (HFA) of the ESC Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-27
Antoni Bayes‐Genis, Matteo Pagnesi, Pau Codina, William T. Abraham, Offer Amir, Rudolf A. de Boer, Jasper J. Brugts, Ovidiu Chioncel, Finn Gustafsson, JoAnn Lindenfeld, Wilfried Mullens, Mark C. Petrie, Giuseppe Rosano, Marco MetraEpisodes of worsening heart failure (HF) are a major cause of unplanned hospitalizations. Their onset is usually preceded by an early increase in intracardiac pressures with subsequent worsening of symptoms due to congestion. Implantable devices allowing daily remote pulmonary artery pressure (PAP) monitoring are useful to identify early haemodynamic changes so that medical therapy can be adjusted
-
Heart failure in patients with a systemic right ventricle: A multicentre study with long‐term follow‐up Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-25
Mohammad Mostafa Ansari Ramandi, Werner Budts, Jolien W. Roos‐Hesselink, Willem A. Helbing, Anastasia D. Egorova, Berto J. Bouma, Anthonie Duijnhouwer, Roland van Kimmenade, Gertjan T. Sieswerda, Thelma C. Konings, Lodewijk J. Wagenaar, Joey F.A. Ubachs, Rolf M.F. Berger, Elke S. Hoendermis, Adriaan A. Voors, Joost P. van Melle -
Age‐related penetrance of phospholamban p.Arg14del cardiomyopathy Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-23
Tom E. Verstraelen, Freyja H.M. van Lint, Remco de Brouwer, Virginnio M. Proost, Esmee van Drie, Laurens P. Bosman, Lotte Weverink, Karim Taha, Thais Bueren, Aeilko H. Zwinderman, Cathelijne Dickhoff, Toon Oomen, Bas A. Schoonderwoerd, Tjeerd Germans, Arjan C. Houweling, Juan R. Gimeno‐Blanes, Folkert W. Asselbergs, Paul A. van der Zwaag, Anneline S.J.M. te Riele, Rudolf A. de Boer, Maarten P. van -
The use of left ventricular ejection fraction in the diagnosis and management of heart failure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS) Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-22
Giuseppe M.C. Rosano, John R. Teerlink, Koichiro Kinugawa, Antoni Bayes‐Genis, Ovidiu Chioncel, James Fang, Barry Greenberg, Nasrien E. Ibrahim, Teruhiko Imamura, Takayuki Inomata, Koichiro Kuwahara, Brenda Moura, Anekwe Onwuanyi, Naoki Sato, Gianluigi Savarese, Yasuhiko Sakata, Nancy Sweitzer, Jane Wilcox, Kazuhiro Yamamoto, Marco Metra, Andrew J.S. CoatsThis clinical consensus statement revisits the role of left ventricular ejection fraction (LVEF) as a measurement of cardiac function, a prognostic marker and a major criterion to classify patients with heart failure, and gives new advice for clinical practice. Heart failure is traditionally classified on the basis of LVEF thresholds and this has major implications for treatment recommendations. However
-
Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction according to body weight Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-21
Jawad H. Butt, Scott D. Solomon, Muthiah Vaduganathan, Dirk J. van Veldhuisen, Lars Køber, Bertram Pitt, Faiez Zannad, Pardeep S. Jhund, John J.V McMurrayAimsObesity is associated with excessive adipocyte‐derived aldosterone secretion, independent of the classical renin–angiotensin–aldosterone cascade, and mineralocorticoid receptor antagonists (MRAs) may be more effective in obese patients with heart failure (HF) with reduced ejection fraction (HFrEF).Methods and resultsUsing individual patient‐level data from two randomized placebo‐controlled trials
-
The interaction between atrial fibrillation and mitral regurgitation: Insights from the CABANA randomized clinical trial Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-21
Sebastiaan Dhont, Philippe B. Bertrand, Jonas Erzeel, Sébastien Deferm, Laurent Pison, Pieter M. Vandervoort, Wilfried Mullens, W.H. Wilson Tang, Pieter Martens -
Minimization or withdrawal of oral pharmacotherapy in chronic heart failure patients with improved myocardial function: A systematic review Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-21
Yuxiang Luo, Wenbin Xiao, Yusuf Z. Sener, Wouter C. Meijers, Robert M.A. van der Boon, Elfatih A. Hasabo, Osama Soliman, Rudolf A. de Boer, Kadir Caliskan -
Issue Information Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-20
Click on the article title to read more.
-
Annals of Neurology: Volume 97, Number 5, May 2025 Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-20
Click on the article title to read more.
-
Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-15
Yasuhiko Sakata, Kotaro Nochioka, Satoshi Yasuda, Koichi Ishida, Takashi Shiroto, Jun Takahashi, Shintaro Kasahara, Ruri Abe, Shinsuke Yamanaka, Takahide Fujihashi, Hideka Hayashi, Shintaro Kato, Katsunori Horii, Kanako Teramoto, Tsutomu Tomita, Satoshi Miyata, Koichiro Sugimura, Iwao Waga, Masao Nagasaki, Hiroaki Shimokawa -
Late diagnosis in cancer sparks outrage—so why not heart failure? Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-15
Antoni Bayes‐Genis, Lisa Anderson, Ed Harding, Marco Metra, John R. Teerlink, James L. Januzzi, Javed Butler, Giuseppe M.C. RosanoClick on the article title to read more.
-
Prediction and prognostic role of left ventricular systolic dysfunction in family screening for dilated cardiomyopathy and non‐dilated left ventricular cardiomyopathy Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-14
Eva Del Mestre, Alessia Paldino, Carola Pio Loco Detto Gava, Ilaria Gandin, Marta Gigli, Davide Stolfo, Martina Setti, Giovanni Maria Severini, Beatrice Spedicati, Stefania Lenarduzzi, Giorgia Girotto, Alessandro Folgheraiter, Jacopo Giulio Rizzi, Renata Korcova, Luisa Mestroni, Marco Merlo, Matteo Dal Ferro, Gianfranco SinagraAimsThe prognostic significance of detecting left ventricular (LV) systolic dysfunction during family screening programmes (FSPs) in relatives of probands affected by dilated (DCM) and non‐dilated left ventricular (NDLVC) cardiomyopathies remain unclear. This study sought to evaluate the prognostic role of LV systolic dysfunction detection in relatives of DCM/NDLVC probands and to define the most accurate
-
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-14
Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Katharina Mueller, Markus F. Scheerer, Prabhakar Viswanathan, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray -
Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-11
Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Meike Brinker, Patrick Schloemer, Prabhakar Viswanathan, Andrea Lage, Katja Rohwedder, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray -
Cardiac rhythm devices in heart failure with reduced ejection fraction – role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-10
Biykem Bozkurt, Wilfried Mullens, Christophe Leclercq, Andrea M. Russo, Gianluigi Savarese, Michael Böhm, Loreena Hill, Koichiro Kinugawa, Naoki Sato, William T. Abraham, Antoni Bayes‐Genis, Alexandre Mebazaa, Giuseppe M.C. Rosano, Shelley Zieroth, Cecilia Linde, Javed ButlerGuidelines for management of heart failure with reduced ejection fraction (HFrEF) emphasize personalized care, patient engagement, and shared decision‐making. Medications and cardiac rhythm management (CRM) devices are recommended with a high level of evidence. However, there are significant disparities: patients who could benefit from devices are frequently referred too late or not at all. Misconceptions
-
Letter regarding the article ‘Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta-analysis’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-09
Jian HuangClick on the article title to read more.
-
Reply to the letter regarding the article ‘Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta-analysis’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-04-09
Paschalis Karakasis, Eleftheria Lefkou, Konstantinos Pamporis, Stephane Heymans, Gerasimos Filippatos, Nikolaos FragakisClick on the article title to read more.